Pfizer loses landmark second medical use patent case
The UK Supreme Court has ruled against Pfizer in a long-running legal battle over the validity of a second medical use patent protecting pregabalin.
Read More
Tag: Actavis
BIA gets green light to intervene in Actavis/ICOS patent case
The Supreme Court has given its consent to the UK’s BioIndustry Association (BIA) to intervene in a case that the latter says “could have far-reaching impacts on the life sciences sector”.
Read More
Lilly victorious in Alimta patent case
Eli Lilly has welcomed a decision by the UK Supreme Court that alternative salt forms of its cancer drug Alimta, marketed by Teva’s Actavis, directly infringe on its vitamin regimen patents in the UK, France, Spain and Italy, overturning previous High Court and Court of Appeal judgements.
Read More
Pfizer loses second medical use patent case
Pfizer says it is disappointed with a UK Court of Appeal ruling backing an earlier judgement that its patent protecting pregabalin for pain has not been infringed by Actavis.
Read More
Teva divests UK, Ireland assets
Teva Pharmaceutical Industries is planning to sell off assets and operations of Actavis Generics in the UK and Ireland to Intas Pharmaceuticals subsidiary Accord Healthcare for £603 million.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
